{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T09:29:33Z","timestamp":1782034173105,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s13555-025-01356-8","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:02:52Z","timestamp":1740106972000},"page":"707-719","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["PSO-TARGET: a New Tool to Identify the Therapeutic Expectations of Psoriasis Patients Treated with Biologics"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct04765332","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4844-3559","authenticated-orcid":false,"given":"Ziad","family":"Reguiai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Dominique","family":"Ghislain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Moulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Baudier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corentin","family":"Schepkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Sint\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Boy\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"1356_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020. https:\/\/doi.org\/10.1136\/bmj.m1590.","journal-title":"BMJ"},{"key":"1356_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.21608\/bjas.2021.188838","volume":"6","author":"FM El-esawy","year":"2021","unstructured":"El-esawy FM, Salem RM, Elsayed IA, El-fallah AA, Farag MA. Factors affecting response to psoriasis treatment. Benha J Appl Sci. 2021;6:183\u20136. https:\/\/doi.org\/10.21608\/bjas.2021.188838.","journal-title":"Benha J Appl Sci"},{"key":"1356_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12589","author":"JF Merola","year":"2018","unstructured":"Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018. https:\/\/doi.org\/10.1111\/dth.12589.","journal-title":"Dermatol Ther"},{"key":"1356_CR4","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/j.1468-3083.2010.03705.x","volume":"24","author":"A Kimball","year":"2010","unstructured":"Kimball A, Gieler U, Linder D, Sampogna F, Warren R, Augustin M. Psoriasis: is the impairment to a patient\u2019s life cumulative? Acad Dermatol Venereol. 2010;24:989\u20131004. https:\/\/doi.org\/10.1111\/j.1468-3083.2010.03705.x.","journal-title":"Acad Dermatol Venereol"},{"key":"1356_CR5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1046\/j.1087-0024.2003.09110.x","volume":"9","author":"J De Korte","year":"2004","unstructured":"De Korte J, Mombers FMC, Bos JD, Sprangers MAG. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc. 2004;9:140\u20137. https:\/\/doi.org\/10.1046\/j.1087-0024.2003.09110.x.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"1356_CR6","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/bjd.21593","volume":"187","author":"C Blome","year":"2022","unstructured":"Blome C, Von St\u00fclpnagel CC, Augustin M, Mrowietz U, Reich K, Muehlan H, et\u00a0al. Measuring patient-relevant benefits in the treatment of psoriasis with the Patient Benefit Index: development and preliminary validation of a 10-item short form. Br J Dermatol. 2022;187:588\u20139. https:\/\/doi.org\/10.1111\/bjd.21593.","journal-title":"Br J Dermatol"},{"key":"1356_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/jdv.12106","volume":"28","author":"PL Mattei","year":"2014","unstructured":"Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. Acad Dermatol Venereol. 2014;28:333\u20137. https:\/\/doi.org\/10.1111\/jdv.12106.","journal-title":"Acad Dermatol Venereol"},{"key":"1356_CR8","doi-asserted-by":"publisher","first-page":"1000776","DOI":"10.3389\/fpubh.2023.1000776","volume":"11","author":"P Maravilla-Herrera","year":"2023","unstructured":"Maravilla-Herrera P, Merino M, Alfonso Zamora S, Balea Filgueiras J, Carrascosa Carrillo JM, Delgado S\u00e1nchez O, et\u00a0al. The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain. Front Public Health. 2023;11:1000776. https:\/\/doi.org\/10.3389\/fpubh.2023.1000776.","journal-title":"Front Public Health"},{"key":"1356_CR9","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/dth.12267","volume":"28","author":"F Kerdel","year":"2015","unstructured":"Kerdel F, Zaiac M. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol Ther. 2015;28:390\u2013403. https:\/\/doi.org\/10.1111\/dth.12267.","journal-title":"Dermatol Ther"},{"key":"1356_CR10","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.12788\/j.sder.2018.010","volume":"37","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Armstrong AW, Wu JJ. Treating to target\u2014a realistic goal in psoriasis? Sem Cutan Med Surg. 2018;37:S44\u20137. https:\/\/doi.org\/10.12788\/j.sder.2018.010.","journal-title":"Sem Cutan Med Surg"},{"key":"1356_CR11","doi-asserted-by":"publisher","first-page":"062","DOI":"10.1684\/ejd.2010.0815","volume":"20","author":"I Sch\u00e4fer","year":"2010","unstructured":"Sch\u00e4fer I, Hacker J, Rustenbach SJ, Radtke M, Franzke N, Augustin M. Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol. 2010;20:062\u20137. https:\/\/doi.org\/10.1684\/ejd.2010.0815.","journal-title":"Eur J Dermatol"},{"key":"1356_CR12","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1159\/000119415","volume":"216","author":"M Augustin","year":"2008","unstructured":"Augustin M, Kr\u00fcger K, Radtke MA, Schwippl I, Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology. 2008;216:366\u201372. https:\/\/doi.org\/10.1159\/000119415.","journal-title":"Dermatology"},{"key":"1356_CR13","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1046\/j.0022-202X.2003.09101.x","volume":"122","author":"F Sampogna","year":"2004","unstructured":"Sampogna F, Sera F, Abeni D. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Investig Dermatol. 2004;122:602\u20137. https:\/\/doi.org\/10.1046\/j.0022-202X.2003.09101.x.","journal-title":"J Investig Dermatol"},{"key":"1356_CR14","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","volume":"70","author":"MG Lebwohl","year":"2014","unstructured":"Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et\u00a0al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70:871-881.e30. https:\/\/doi.org\/10.1016\/j.jaad.2013.12.018.","journal-title":"J Am Acad Dermatol"},{"key":"1356_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s13555-021-00635-4","volume":"12","author":"M Lebwohl","year":"2022","unstructured":"Lebwohl M, Langley RG, Paul C, Pu\u00edg L, Reich K, Van De Kerkhof P, et\u00a0al. Evolution of patient perceptions of psoriatic disease: results from the understanding psoriatic disease leveraging insights for treatment (UPLIFT) survey. Dermatol Ther (Heidelb). 2022;12:61\u201378. https:\/\/doi.org\/10.1007\/s13555-021-00635-4.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1356_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12895-020-00099-7","volume":"20","author":"A Egeberg","year":"2020","unstructured":"Egeberg A, See K, Garrelts A, Burge R. Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort. BMC Dermatol. 2020;20:3. https:\/\/doi.org\/10.1186\/s12895-020-00099-7.","journal-title":"BMC Dermatol"},{"key":"1356_CR17","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1002\/sim.1836","volume":"23","author":"J Li","year":"2004","unstructured":"Li J, Fine J. On sample size for sensitivity and specificity in prospective diagnostic accuracy studies. Stat Med. 2004;23:2537\u201350. https:\/\/doi.org\/10.1002\/sim.1836.","journal-title":"Stat Med"},{"key":"1356_CR18","doi-asserted-by":"publisher","first-page":"D7","DOI":"10.1016\/S0149-2918(03)80246-1","volume":"25","author":"D Cella","year":"2003","unstructured":"Cella D, Chassany O, Fairclough D, Hahn EA, Hays RD, Wong G. A guide for clinicians to compare the accuracy and precision of health-related quality-of-life data relative to other clinical measures. Clin Ther. 2003;25:D7-8. https:\/\/doi.org\/10.1016\/S0149-2918(03)80246-1.","journal-title":"Clin Ther"},{"key":"1356_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12955-019-1084-2","volume":"17","author":"B Forestier","year":"2019","unstructured":"Forestier B, Anthoine E, Reguiai Z, Fohrer C, Blanchin M. A systematic review of dimensions evaluating patient experience in chronic illness. Health Qual Life Outcomes. 2019;17:19. https:\/\/doi.org\/10.1186\/s12955-019-1084-2.","journal-title":"Health Qual Life Outcomes"},{"key":"1356_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-90107-7_1","volume-title":"Evidence-based psoriasis","author":"GW Kimmel","year":"2018","unstructured":"Kimmel GW, Lebwohl M. Psoriasis: overview and diagnosis. In: Bhutani T, Liao W, Nakamura M, editors. Evidence-based psoriasis. Cham: Springer International Publishing; 2018. p. 1\u201316. https:\/\/doi.org\/10.1007\/978-3-319-90107-7_1."},{"key":"1356_CR21","volume-title":"Global report on psoriasis","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Global report on psoriasis. Geneva: World Health Organization; 2016."},{"key":"1356_CR22","doi-asserted-by":"publisher","first-page":"S438","DOI":"10.1016\/j.annder.2014.09.472","volume":"141","author":"M Amy De La Breteque","year":"2014","unstructured":"Amy De La Breteque M, Sigal M-L, Est\u00e8ve E, Le Guyadec T, Maccari F, Reguiai Z, et\u00a0al. \u00c9valuation des param\u00e8tres expliquant la discordance PASI\/DLQI chez les patients atteints de psoriasis. Ann Dermatol Venereol. 2014;141:S438\u20139. https:\/\/doi.org\/10.1016\/j.annder.2014.09.472.","journal-title":"Ann Dermatol Venereol"},{"key":"1356_CR23","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s11136-015-1208-z","volume":"25","author":"F Rencz","year":"2016","unstructured":"Rencz F, Baji P, Gul\u00e1csi L, K\u00e1rp\u00e1ti S, P\u00e9ntek M, Po\u00f3r AK, et\u00a0al. Discrepancies between the Dermatology Life Quality Index and utility scores. Qual Life Res. 2016;25:1687\u201396. https:\/\/doi.org\/10.1007\/s11136-015-1208-z.","journal-title":"Qual Life Res"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01356-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01356-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01356-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T08:04:11Z","timestamp":1741939451000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01356-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1356"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01356-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"31 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prof Dr Pierre-Dominique Ghislain: speaker and hospital investigator for AbbVie, Almirall, Amgen, BMS, Eli Lilly, Flen, Galderma, Janssen, LEO Pharma, Maruho, Meda, Menarini, MSD, Novartis, PellePharm, Pfizer, Serono, UCB et Viatris. Dr Thierry Boy\u00e9: Personal fees and grant (clinical research) Novartis, LEO Pharma, Janssen, Abbvie, Amgen, Lilly, UCB. Dr Ziad Reguiai: Abbvie, Almirall, Amgen, Celltrion, Boerhinger-Ingelheim, Bristol-Meyers-Squibb, Celgene, Eli Lilly, Incyte, Janssen, LEO Pharma, Medac, MSD, Novartis, Pfizer, UCB. Prof Pierre Moulin: No conflict of interest. Emilie Baudier: Employee of LEO Pharma, Belgium. Corentin Schepkens: Corentin Schepkens who was affiliated to LEO Pharma NV\/SA, Lier, Belgium at the time of study and publication is now affiliated to MSD, Belgium. He worked for LEO Pharma, Belgium during the statistical analysis and the drafting of the manuscript. Maxime Sint\u00e8s: Employee of LEO Pharma, France.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was approved by the Ethics Committee OUEST III on 13th of May 2020 in France, and the Ethics Committees of UC Louvain on 3rd of February 2021 in Belgium. All patients included in the study provided their signed, informed consent to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}